Two of the World's Top Geneticists are Coming to Miami
News Nov 10, 2006
Two of the most acclaimed geneticists in the world, Dr. Margaret Pericak-Vance and Dr. Jeffery Vance of Duke University, are bringing their pioneering research into the genetics of a multitude of diseases to Miami.
The Vances' Center for Human Genetics at Duke has uncovered critical clues to the origins of diseases including Parkinson's, Alzheimer's, age-related macular degeneration, multiple sclerosis, autism and the muscular dystrophies.
At the University of Miami Miller School of Medicine, they will lead a team of investigators that will make up a new Institute of Human Genomics and a proposed Department of Human Genetics.
"The state of Florida is making substantial strides in recruiting some of the very best scientific institutes and centers to our region," said Pascal J. Goldschmidt, M.D., senior vice president for medical affairs and dean of the Miller School.
"A paradigm for this remarkable opportunity for the citizens of Florida is the recruitment of the Center for Human Genetics, led by Margaret and Jeff Vance."
Her use of novel disease gene mapping led in 1993 to the identification of the major susceptibility gene for Alzheimer's disease apolipoprotein E and very recently to the discovery of a gene that determines risk for developing age-related macular degeneration.
Jeffery Vance, Ph.D., M.D., is the associate director of the Duke Center for Human Genetics, professor of medicine, and director of the Morris K. Udall Parkinson Disease Research Center of Excellence at Duke.
His lab has found and studied genes that contribute to diseases including Parkinson's, Alzheimer's, cardiovascular disease, and one of the most common inherited neurological disorders, Charcot-Marie-Tooth Disease.
"Jeff and I love to build things, we love to be creative when we build things, and we like to think outside the box," Pericak-Vance said.
"This is the opportunity to build something truly outstanding and to integrate all of the University of Miami's strengths into one program."
"Genomic medicine is going to change the way we practice medicine from being reactive to being proactive," she said.
"We will discover ways to prevent disease, and we will find better treatments that are based on understanding the complex causes underlying the disorders."
"We have the power now to sort this out and to look at the whole picture."
UM President Donna E. Shalala said the Vances "lead the field of human genetics, particularly as it relates to the common illnesses that all of us are exposed to neurological disorders, heart disease, cancer, vision impairment."
"In Miami they will lead one of the premier institutes for human genomics in the world."
The Duke team includes several other investigators who will also be moving to South Florida.
"We're a very integrated group, we’re multidisciplinary, and we work together on a daily basis," Jeffery Vance said.
"Miami is just a tremendous opportunity to continue to grow, and to begin to translate some of these genes that we're finding into actual practice. That's the ultimate goal."
"The University has two of the best academic leaders in the country: Pascal Goldschmidt and Donna Shalala," he added.
"And there are some terrific researchers in diabetes, spinal cord injury, cancer, eye disease, autism, and many other areas who present real opportunities for collaboration."
Dean Goldschmidt said the Miami genomics institute "will create a formidable opportunity to apply the new knowledge brought out by the Human Genome Project and translate this knowledge in findings that will help our patients survive some of the most deadly diseases."
"They will bring this opportunity not only to all of us at the University of Miami Miller School of Medicine, but also to everyone involved in biomedical research in South Florida, including Florida International University, Florida Atlantic University, the Scripps Research Institute and many other groups."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018